

Adcendo to Participate in Expert ADC Panel Debate at BIO-Europe 2024

Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announces that its CEO, Michael Pehl will join fellow antibody-drug-conjugate (ADC) industry leaders and experts on a panel discussion at the [30th Annual BIO-Europe](#) conference, held in Stockholm, Sweden, from 4th-6th November 2024.

The panel discussion at this year's BIO-Europe event will explore the rapidly expanding ADC sector and provide insights into the current landscape. Panellists will share perspectives on the latest innovations and challenges facing ADC development, as well as the future of ADCs and their potential to reshape the paradigm of precision medicine.

Panel discussion details:

Panel Title: "Two for the Price of One!" The ADC arena

Speaker: Michael Pehl, CEO of Adcendo

Panel Date and Time: Tuesday 5 November, 2024, 14:00 CET

Venue: Stockholmsmässan, Mässvägen 1, 125 30 Älvsjö, Stockholm, Sweden

Location: Room K2

2024 has been a transformative year for Adcendo as the Company shortly transitions into becoming a clinical-stage biotech with two first-in-class programs, ADCE-T02, targeting Tissue Factor (TF) in multiple epithelial cancers, and ADCE-D01, targeting uPARAP in patients with metastatic and/or unresectable STS, entering the clinical stage of development. A Clinical Trial Notification has been submitted for ADCE-T02 in Australia with FPI planned in Q4 2024, and Adcendo has recently received [US FDA IND clearance](#) to commence a first-in-human Phase I/II study (ADCElerate-01 Trial) of ADCE-D01.

- ENDS -

For further information:

Optimum Strategic Communications

Mary Clark, Zoe Bolt, Elena Bates

Tel: +44 (0) 203 882 9621

E-mail: adcendo@optimumcomms.com

Adcendo ApS

Michael Pehl, CEO

Tel: +45 31541824

Email: info@adcendo.com

About Adcendo ApS:

Adcendo ApS is developing breakthrough antibody-drug conjugates for the treatment of underserved cancers. In 2024, the company completed a Series A extension financing round, increasing the total funds raised to 98M EUR to advance, broaden, and accelerate the development of its first-in-class ADC pipeline

assets. Investors include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, Gilde Healthcare and Dawn Biopharma, a platform controlled by KKR. For further information, please visit www.adcendo.com.

BIO-Europe:

BIO-Europe, Europe's leading partnering event, provides an exceptional opportunity to connect with delegates spanning the global life science ecosystem to propel dealmaking and innovation. The event will bring together over 5,500 attendees, representing more than 2,800 companies and over 60 countries. BIO-Europe will feature a distinguished lineup of speakers, including leading experts and visionaries from the biotech and pharma industries, who will take attendees on a journey of the past 30 years of experiences, partnerships and innovation and envision trends in the next 30 years to come.